Table 2.
CD50 (minutes), Cr ratio (%), and the relation to AD classification of each ophthalmic solution and additive
| Ophthalmic solution | CR (%) | CDT50 (minutes) | AD classification |
|---|---|---|---|
| Latanoprost (Xalatan®) | 82.0 | 11.6 | A1D2 |
| Tafluprost (Tapros®) | 113.2 | >60 | A0D0 |
| Bimatoprost (Lumigan®) | 118.0 | 50.5 | A0D0 |
| Travoprost (Travatan®) | 81.0 | 25.3 | A1D1 |
| Travoprost (Travatan Z®) | 96.6 | 51.0 | A0D0 |
| BAK (0.005%) | 105.0 | 14.5 | A0D0 |
| BAK (0.01%) | 90.5 | 8.1 | A1D1 |
| BAK (0.02%) | 68.7 | 4.0 | A2D2 |
| HCO-40 (0.1%) | 108.7 | 24.6 | A0D0 |
| P-80 (0.1%) | 114.2 | 37.2 | A0D0 |
Notes: Cell injuries were the most severe with BAK, followed by P-80 and HCO-40. The CR ratio (%) significantly decreased with latanoprost (82.0%, 2 minutes after instillation) and with travoprost (81.0%, 30 minutes after instillation), but recovered as time advanced (P < 0.05). On the other hand, a decrease in the Cr ratio was rarely observed with travoprost-Z. The CR ratio with tafluprost or bimatoprost did not decrease, and tended to be slightly higher after instillation.
Abbreviations: CD50, exposure time causing 50% cell damage; Cr, corneal resistance; AD, area density; BAK, benzalkonium chloride; P-80, polysorbate 80; HCO-40, polyoxyethylene hardening castor oil 40.